Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis

Sponsor
Hvidovre University Hospital
Study ID
NCT00216177
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Infliximab — DRUG
    Remicade
  • Adalimumab — DRUG
    Humira

Study Details

The purpose of this study is to establish whether RA patients with moderate to severe disease activity with unsustainable response to infliximab 3 mg/kg every 8 weeks have better efficacy with adalimumab 40 mg s.c. eow compared to infliximab 3 mg/kg i.v. every 6 weeks.

Key Dates

Start date
Sep 30, 2005
Status verified
Aug 2009
Primary completion
Jan 31, 2009
Completion
Jun 30, 2009

Study Design

Enrollment
112 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

Proportion of patients achieving combined good or moderate EULAR responses at week 24 [ Time Frame: six months ]

Central Contacts

Related Studies